Anavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
October 27 2017 - 8:52AM
ANAVEX®2-73 Shown to Protect and Repair Myelin
Forming Cells
Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a
clinical-stage biopharmaceutical company developing differentiated
therapeutics for the treatment of neurodegenerative and
neurodevelopmental diseases including Alzheimer’s disease, other
central nervous system (CNS) diseases, pain and various types of
cancer, today announced additional data from a preclinical study of
ANAVEX®2-73 related to multiple sclerosis. The data was
presented in an oral presentation by lead investigator, Robert
Lisak, MD, Professor of Neurology at Wayne State University School
of Medicine, at the 7th Joint ECTRIMS-ACTRIMS Meeting MSPARIS2017.
|
Oral
Presentation Details: |
|
|
|
|
|
|
|
|
|
|
|
|
Session: |
|
|
|
|
|
|
|
|
|
|
Remyelination: from
biology to clinical trials |
Title: |
|
|
|
|
|
|
|
|
|
|
Sigma 1 receptor
agonists as potential protective and reparative therapy in
multiple sclerosis |
|
|
|
|
|
|
|
|
|
|
|
|
Date: |
|
|
|
|
|
|
|
|
|
|
October 27, 2017 |
Time: |
|
|
|
|
|
|
|
|
|
|
2:52 pm ECT |
Location: |
|
|
|
|
|
|
|
|
|
|
Hall B, Le Palais des
Congrès de Paris |
|
|
|
|
|
|
|
|
|
|
|
2 Place de la Porte
Maillot |
|
|
|
|
|
|
|
|
|
|
|
75017 Paris,
France |
|
|
|
|
|
|
|
|
|
|
|
|
“A unique feature of ANAVEX2-73, compared to
another sigma-1 receptor agonist we studied, is that ANAVEX2-73
accelerates the maturation of oligodendrocyte precursor cells (OPC)
to oligodendrocytes (OL),” said Dr Robert P. Lisak. “This is an
important feature since OPCs can replace lost OLs by maturing into
new potential myelin-producing cells. In other words, ANAVEX2-73
might promote remyelination. Further data also demonstrates that
ANAVEX2-73 provides protection for OL, OPCs, as well as central
nervous system neurons in addition to helping repair by increasing
OPC proliferation and maturation in tissue culture.“
“These findings provide additional evidence for
the neuroprotective and neurorestorative effects of ANAVEX2-73, as
well as further validating the mechanism of our target,” said
Christopher U. Missling, PhD, President and Chief Executive Officer
of Anavex.
About Multiple
sclerosisMultiple sclerosis (MS) is a chronic autoimmune
disease that causes damage to nerve fibers in the central nervous
system (CNS), including the brain, spinal cord and optic nerve.
This can disrupt communication between the CNS and other parts of
the body, resulting in a wide range of physical and cognitive
symptoms such as muscle weakness, visual loss, poor balance,
chronic pain, tremors, short-term memory loss and other
difficulties associated with dementia.
About Anavex Life Sciences
Corp.Anavex Life Sciences Corp. (Nasdaq:AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of differentiated therapeutics for the treatment of
neurodegenerative and neurodevelopmental diseases including
Alzheimer’s disease, other central nervous system (CNS) diseases,
pain and various types of cancer. Anavex’s lead drug candidate,
ANAVEX®2-73, recently completed successfully a Phase 2a clinical
trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available
drug candidate that restores cellular homeostasis by targeting
sigma-1 and muscarinic receptors. Preclinical studies demonstrated
its potential to halt and/or reverse the course of Alzheimer’s
disease. It has also exhibited anticonvulsant, anti-amnesic,
neuroprotective and anti-depressant properties in animal models,
indicating its potential to treat additional CNS disorders,
including epilepsy. The Michael J. Fox Foundation for Parkinson’s
Research has awarded Anavex a research grant to develop ANAVEX®2-73
for the treatment of Parkinson’s disease to fully fund a
preclinical study, which could justify moving ANAVEX®2-73 into a
Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting
sigma-1 and M1 muscarinic receptors, is a promising preclinical
drug candidate demonstrating disease modifications against the
major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including
cognitive deficits, amyloid and tau pathologies, and also with
beneficial effects on neuroinflammation and mitochondrial
dysfunctions. Further information is available at www.anavex.com.
You can also connect with the company on Twitter, Facebook and
LinkedIn.
Forward-Looking
StatementsStatements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:Anavex
Life Sciences Corp.Research & Business DevelopmentToll-free:
1-844-689-3939Email: info@anavex.com
Investors & Media:Clayton RobertsonThe
Trout Group(646) 378-2900crobertson@troutgroup.com
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2023 to Apr 2024